Wos Kapalı Erişimli Yayınlar
Permanent URI for this collectionhttps://hdl.handle.net/11727/10753
Browse
3 results
Search Results
Item Left Atrial Mechanics For Secondary Prevention From Embolic Stroke Of Undetermined Source(2022) Sade, Leyla Elif; Keskin, Suzan; Can, Ufuk; Colak, Ayse; Yuce, Deniz; Ciftci, Orcun; Ozin, Bulent; Muderrisoglu, Haldun; https://orcid.org/0000-0003-3737-8595; 33206942; AAQ-7583-2021Aims Anticoagulation is not justified unless atrial fibrillation (AF) is detected in cryptogenic stroke (CS) patients. We sought to explore whether left atrial (LA) remodelling is associated with embolic stroke of undetermined source (ESUS). Methods and results In this prospective study, we evaluated consecutively 186 patients in sinus rhythm who presented with an acute ischaemic stroke (embolic and non-embolic) and sex- and age-matched controls. We performed continuous electrocardiogram (ECG) monitoring to capture paroxysmal AF episodes as recommended by the guidelines. After 12 months of follow-up, continuous ECG monitoring was repeated in patients with undetected AF episodes. We quantified LA reservoir and contraction strain (LASr and LASct) by speckle-tracking, LA volumes by 3D echocardiography. Out of 186 patients, 149 were enrolled after comprehensive investigation for the source of ischaemic stroke and divided into other cause (OC) (n = 52) and CS (n = 97) groups. CS patients were also subdivided into AF (n = 39) and ESUS (n = 58) groups. Among CS patients, LA strain predicted AF independently from CHARGE-AF score and LA volume indices. ESUS group, despite no captured AF, had significantly worse LA metrics than OC and control groups. AF group had the worst LA metrics. Moreover, LASr predicted both CS (embolic stroke with and without AF) and ESUS (embolic stroke with no detected AF) independently from LAVImax and CHA(2)DS(2)-VASc score. LASr >26% yielded 86% sensitivity, 92% specificity, 92% positive, and 86% negative predictive values for the identification of ESUS (areas under curve: 0.915, P < 0.0001, 95% confidence interval: 0.86-0.97). Conclusion Echocardiographic quantification of LA remodelling has great potential for secondary prevention from ESUS.Item Risk factors for left atrial appendage thrombus(2020) Yilmaz, Kerem Can; Akgun, Arzu Neslihan; Ciftci, Orcun; Eroglu, Serpil; Pirat, Bahar; Sade, Elif; Ulucam, Melek; Ozin, Bulent; Muderrisoglu, Haldun; 0000-0002-9635-6313; 0000-0001-8926-9142; 0000-0003-4576-8630; 0000-0003-3055-7953; 32342731; AAD-9938-2021; AAG-8233-2020; W-5233-2018; AAI-8897-2021; AAJ-1331-2021Background: Atrial fibrillation (AF) is the most common persistent rhythm disorder that has been shown to be associated with a significant increase in stroke risk. Left atrial appendage (LAA) thrombi are responsible for most of strokes of cardiac origin. CHA(2)DS(2)-VASc is a risk scoring system to identify patients' indications for anticoagulation in nonvalvular AF patients. The aim of our study was to investigate CHA(2)DS(2)-VASc score, the other risk factors, echocardiographic data and blood parameters for LAA thrombus. Methods: Two hundred and sixty-four patients who were admitted to our adult cardiology outpatient clinic and who underwent a transesophageal echocardiography procedure between June 2017 and June 2019 included in our study. Patient's demographic data, transthoracic echocardiographic examinations, and laboratory results were recorded retrospectively. Results: LAA thrombus was detected in 39 (14.7%) patients. The rates of coronary artery disease and systolic dysfunction were significantly higher in patients with LAA thrombus (p = .017, p = .016, respectively). When AF subtypes were examined in detail, thrombus rate was significantly higher in persistent AF (51 vs. 25.7%, p = .002). Although the CHA(2)DS(2)-VASc score was slightly higher in the thrombus group, there was no statistically significant difference between the two groups (3.0 +/- 1.65 vs. 2.78 +/- 1.66). Conclusions: In conclusion, CHA(2)DS(2)-VASc score system itself was not informative about LAA thrombus formation although some of its components were related with LAA thrombus formation. According to a multiple regression analysis, the independent determinants of LAA thrombus were the presence of AF and coronary artery disease.Item Cost analysis of management of cardiovascular disease comorbidities in Turkey(2019) Kockaya, Guvenc; Oguzhan, Gulpembe Ergin; Ozin, Bulent; Yilmaz, Kerem Can; Ciftci, Orcun; Cavus, Filiz; Sharaf, Mustapha; Buyuktuna, Nazim; Buyukisik, Tansu; Saylan, MeteObjectives The strongest muscle of human body, the heart, is susceptible to a range of diseases. These diseases involve deterioration of the blood vessels, muscles of heart, malformation of cardiovascular structures, tumour formations, formation of clots, rupturing of vessels and others. Therefore, taking into consideration the direct and indirect burdens of cardiovascular diseases around the globe, the present study was designed to perform a direct cost analysis of managing comorbidities of cardiovascular diseases with reimbursement authority perspective. Methods The cost analysis study conducted in the present article was conducted in three phases. The first phase involved filling of survey questionnaire by five experts practicing in the field of cardiology in Turkey. The second phase comprised of expert panel wherein three out of five experts reviewed the forms filled by all the experts. This was followed by third phase wherein the three experts attending the panel re-filled the questionnaire as per the daily clinical practice. Key Findings The findings showed total annual costs for cardiovascular diseases (CVDs) exhibiting myocardial infarction comorbidities for both acute and maintenance treatment as 5622.95 and 1245.04 TL respectively. The total costs for major bleeding events were found to be 1211.95 TL, whereas for minor bleeding events the costs were 496.26 TL. The total cost for intracranial bleeding was 1761.53, and 3595.62 TL for stroke, which followed myocardial infarction. Conclusion The study findings helped gain an insight into the most prominent comorbidities associated with CVDs in the perspective of reimbursement institution including direct costs. Further studies are needed to understand the real cost for reimbursement institution.